Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

• Status: Terminated
• Trial end date: 2016-07-01

Summary

Primary Objective:

To assess the long-term safety of vatelizumab in MS patients

Secondary Objective:

To assess the long-term efficacy of vatelizumab

• Phase: Phase 2

Details

• Lead Sponsor: Genzyme, a Sanofi Company